Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare Part B Payment Boost For Biosimilars A Positive Step But ‘More Must Be Done’

Executive Summary

The policy is welcomed by biosimilar stakeholders, but amounts to a relatively small increase. To qualify for the revised payment, a biosimilar must have an average sales price that is less than its reference drug’s ASP and not all do.

You may also be interested in...



Biosimilars in Medicare Part B: CMS Weighing Payment Demonstration To Boost Uptake

Agency cites possible demonstration in response to HHS Office of Inspector General report urging reimbursement reforms to spur greater use of biosimilars and lower costs for Medicare and beneficiaries.

Biosimilars in Medicare Part B: CMS Weighing Payment Demonstration To Boost Uptake

Agency cites possible demonstration in response to HHS Office of Inspector General report urging reimbursement reforms to spur greater use of biosimilars and lower costs for Medicare and beneficiaries.

Down But Not Out: The Pharma Policies That Still May Ride With Senate Finance’s PBM Reform

A new biosimilar payment boost, a true, but more limited patient-directed pass-through rebate plan, and product hopping legislation are among the more than two-dozen amendments that could be added to the Senate Finance Committee’s PBM reform package. 

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS147115

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel